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Breast and prostate cancers afflict women and men, respectively,
more frequently than any other malignancies. Approximately
40 000 Americans die from each of these cancers every year.
Despite the advances in molecular medicine over the last 20 years,
our understanding of the pathogenesis of sporadic breast and
prostate cancers remains incomplete. Recently, a number of
epidemiological, genetic and biochemical similarities between
these two hormonally-dependent cancers have been illuminated
(Lopez-Otin and Diamandis, 1998), including the expression of
proteins initially thought to be restricted to prostatic tissue but now
also demonstrated in female breast tissue. The prototype of such
proteins is prostate-specific antigen (PSA), which has been shown
to be expressed by normal, hyperplastic and cancerous breast
epithelium and can be detected in breast secretions including
colostrum, nipple aspirate fluid (NAF) and breast cyst fluid
(Diamandis and Yu, 1995, 1997). Studies in which several breast
cancer cell lines were stimulated with steroid hormones has
revealed that expression of PSA mRNA and protein is androgen
and progestin-regulated (Zarghami et al, 1997). The role of PSA in
breast pathophysiology is unknown, although clues have been
provided by observations that its expression is more common in
steroid hormone receptor-positive tumours (Diamandis et al,
1994), in smaller, more well-differentiated lesions, and in tumours
from younger patients and those who have a favourable clinical
prognosis (Yu et al, 1995, 1998).
PSA is a member of the kallikrein family (McCormack et al,
1995), which consists of human glandular kallikrein (hK) 1, hK2
and hK3 (PSA). These genes show extensive sequence homology
and localize within a 60 kb region of chromosome
19q13.3–q13.4 (Reigman et al, 1992). Whereas hK1 is widely
expressed in various tissues, including kidney and pancreas,
expression of both hK2 and hK3 was generally considered
prostate-specific until female breast epithelial cells were shown
to express and secrete PSA (Diamandis and Yu, 1995, 1997).
Extra-prostatic sources of hK2 protein have also been identified
in two recent reports, one of which described expression of hK2
by the breast carcinoma cell line T-47D after stimulation by
steroid hormones (Hsieh et al, 1997), and another in which the
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putatively prostate-restricted, steroid hormone-regulated protease may also be expressed in breast epithelium in vivo and secreted into the
mammary duct system. Given that the only substrate yet identified for hK2 activity is the precursor of prostate-specific antigen (PSA), the
expression of which in breast carcinomas may be associated with favourable prognosis, our purpose was to examine the expression pattern
of both hK2 and PSA in breast tumour tissues. Cytosolic extracts of 336 primary breast carcinomas prepared for routine oestrogen receptor
(ER) and progesterone receptor (PR) analysis, as well as 31 nipple aspirates from six women with non-diseased mammary glands, were
assayed for hK2 and PSA using immunofluorometric assays developed by the authors. In the tumour extracts, measurable hK2 and PSA
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Higher concentrations of PSA and hK2 were found in tumours expressing steroid hormone receptors (P = 0.0001 for PSA and P = 0.0001 for
hK2, by Wilcoxon tests for both ER and PR), and both PSA (r = 0.25, P = 0.0001) and hK2 (r = 0.22, P = 0.0001) correlated directly with PR
levels. A negative correlation between patient age and PSA (r = –0.12, P = 0.03) was also found. Both proteins were present in nipple aspirate
fluid at relatively high concentrations which were positively correlated (r = 0.53, P = 0.002). The molecular weights of the immunoreactive
species quantified by the hK2 and PSA assays were established by high-performance liquid chromatography (HPLC) and were consistent
with the known molecular weights of hK2 and PSA. Together these data provide the first evidence, to our knowledge, that both malignant
breast tissue and normal breast secretion contain measurable quantities of hK2, and that the degree of hK2 expression or secretion is directly
proportional to the expression of PSA and steroid hormone receptors. hK2 expression may therefore be a marker of steroid hormone action
in breast tissue. © 2000 Cancer Research Campaign
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tumours (Clements et al, 1996).
Recently, work by several groups has suggested the possible
parallel expression of PSA and hK2 by prostate and other tissues.
hK2, a potent trypsin-like protease, was found able to proteolyti-
cally cleave enzymatically inactive pro-PSA into mature, active
PSA which has chymotrypsin-like activity (Kumar et al, 1997;
Lovgren et al, 1997; Takayama et al, 1997). The co-expression of
PSA and hK2 by breast tumours may therefore be based on the
ability of pro-PSA, expression of which is hormonally induced, to
be activated by the action of co-secreted hK2. We have suggested
earlier that enzymatically active PSA may act upon known or
unknown substrates to mediate growth-inhibitory or growth-
promoting signals (Diamandis, 1996). Among the putative PSA
substrates are latent transforming growth factor-b (Killian et al,
1993), insulin-like growth factor binding protein-3 (IGFBP-3)
(Cohen et al, 1992), a kinin-like protein (Fichtner et al, 1996) and
parathyroid hormone related peptide (Cramer et al, 1996).
Until very recently, the ability to discriminate between PSA and
hK2 protein expression has been limited by factors related to
their similar structures. In particular, their extensive sequence
homology prompted the notion that antibodies raised against either
PSA or hK2 will likely cross-react with both antigens. However,
monoclonal anti-PSA antibodies free of cross-reactivity to hK2
(Corey et al, 1997), and anti-hK2 monoclonal antibodies free of
cross-reactivity to PSA (Saedi et al, 1995; Finlay et al, 1998), have
now been developed. The availability of these reagents has, in
turn, facilitated the development of highly specific immunoassays
for hK2 and PSA (Ferguson et al, 1996; Piironen et al, 1996;
Finlay et al, 1998). Evaluation of the cross-reactivities of these
antibodies was initially compromised by the inability to isolate
either PSA or hK2 from seminal plasma without significant conta-
mination from the other protein. With the recent availability of
recombinant hK2 and PSA proteins, this obstacle has also been
overcome (Lovgren et al, 1995; Saedi et al, 1995).
In this paper, we present a study which examined the expression
levels of both hK2 and PSA in a series of 336 breast tumour
cytosolic extracts with respect to each other as well as to their
relationships with two clinically important variables – steroid
hormone receptors and patient age. The presence of hK2 and PSA
in NAF collected from women without apparent breast pathology
was also investigated.
MATERIALS AND METHODS
Breast tumour cytosolic extracts
This use of human specimens in this study was approved by the
Ethics and Research Committee at the University of Toronto. A
series of primary breast carcinomas were obtained from 336
females at hospitals collaborating in the Ontario Provincial
CEA/Steroid Receptor programme. The breast tumour tissue was
snap-frozen in liquid nitrogen immediately after surgical resection,
transported as such to the laboratory, and subsequently stored for
fewer than 2 weeks at –70°C until extraction was performed.
Approximately 0.5 g of tumour tissue was first pulverized at liquid
nitrogen temperature, and the resulting powder was combined
with 10 ml of extraction buffer (10 mM Tris–HCl, pH 7.40,
containing 1.5 mM EDTA and 5 mM sodium molybdate). The
suspended tissue powder was solubilized on ice with a single 5 s
burst of a Polytron homogenizer (Brinkmann Instruments,
Westbury, NY, USA), after which the particulate material was
pelleted by centrifugation at 105 000 g for 1 h. The intermediate
layer (cytosolic extract) was collected without disturbing the lipid
or particulate layers. Protein concentrations of the cytosolic
extracts were determined by the Lowry method. Following steroid
hormone receptor quantification, the remainders of the extracts
were stored at –70°C for not more than 3 months until PSA and
hK2 immunoassay analyses.
Nipple aspirate fluids
NAFs were obtained from six women, three of which were
premenopausal, using the method described in our previous report
(Sauter et al, 1996). From each patient, five to six specimens were
collected over a 3-month period; 31 NAFs were collected in total.
These NAFs, approximately 1–3 ml each, were diluted to 500 ml as
described previously (Sauter et al, 1996) and then analysed for
PSA, hK2 and total protein.
Immunochemical assays
For quantitative analyses of ER and PR, enzyme immunoassay
kits (Abbott Laboratories, North Chicago, IL, USA) were used
according to the manufacturer’s instructions. Concentrations of
steroid hormone receptors were expressed as fmol of oestrogen
receptor (ER) or progesterone receptor (PR) per mg of total protein
to adjust for variabilities in specimen masses and extraction
efficiencies. The determination of PSA concentrations by time-
resolved immunofluorometric assay was performed as described
elsewhere (Ferguson et al, 1996). The PSA assay has a detection
limit of 1 ng l–1 (0.001 mg l–1) and has no detectable cross-reactivity
to hK2. This assay measures free PSA and PSA bound to its major
binding protein, a-1-antichymotrypsin (PSA-ACT), on an
equimolar basis. A new time-resolved immunofluorometric assay
developed by our group was used to measure hK2 concentrations
(Black et al, 1999). The latter assay has a detection limit of 6 ng l–1
(0.006 mg l–1) and has less than 0.2% cross-reactivity to PSA.
Calibration of the PSA assay was performed using highly purified
seminal plasma PSA (Ferguson et al, 1996), whereas calibration of
the hK2 assay was performed using recombinant hK2 (Black et al,
1999). Results of both immunofluorometric assays were expressed
as ng of PSA or hK2 per g of total protein.
High-performance liquid chromatography
The molecular weights of the immunoreactive species in the breast
tumour cytosols were estimated by HPLC using a Superdex 200
gel filtration column (Pharmacia Biotech, Montreal, PQ, Canada)
and an HP 1100 series HPLC system (Hewlett-Packard,
Mississauga, ON, Canada). The mobile phase consisted of a 50
mM Tris buffer, pH 7.4, containing 0.15 M sodium chloride, which
was used at a flow rate of 0.4 ml min–1. For each run, a 200 ml
volume of tumour cytosol was injected, and 400 ml fractions were
collected and assayed for PSA and hK2 as described above.
Calibration was achieved by HPLC fractionation under the same
conditions of a molecular weight standard solution (BioRad
Laboratories, Hercules, CA, USA) containing thyroglobulin
(Mr 670 000), IgG (Mr 158 000), ovalbumin (Mr 44 000),
myoglobin (Mr 17 000) and cyanocobalamin (Mr 1400).
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Associations between PSA, hK2, ER and PR were examined by
Spearman correlation and Wilcoxon rank sum tests. Two-sided P-
values of 0.05 or less were considered statistically significant.
RESULTS
The total protein concentrations in the breast tumour extracts were
normally distributed with a mean of 1.60 g l–1 and a standard devia-
tion of 0.5 g l–1. Based on the detection limits of the PSA and hK2
immunoassays, total protein-adjusted PSA and hK2 concentrations
greater than or equal to 0.6 ng g–1 and 3.8 ng g–1, respectively, were
considered detectable. Among the 336 breast tumour extracts, 73%
had detectable PSA and 53% had detectable hK2. The PSA concen-
trations ranged from 0 to 400 000 ng l–1 and were distributed with a
median of 5.7 ng l–1, a mean of 1408.8 ng l–1, and a standard devia-
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Table 1 Distributions of all numerical variables in 336 breast tumour cytosols
PSA hK2 PSA/hK2 ER PR Age
(ng g–1) (ng g–1) ratioa (fmol mg–1) (fmol mg–1) (years)
Percentile
Minimum <0.6 <3.8 – 0 0 29
5th <0.6 <3.8 – 0 0 35
10th <0.6 <3.8 – 1 1 40
25th <0.6 <3.8 – 7 5 47
50th 3.7 4.2 3.2 57 41 57
75th 38 8.6 8.1 124 216 68
90th 320 29 17 285 410 78
95th 955 79 29 370 502 84
Maximum 400 000 7000 200 980 848 94
Mean 718.3 28.5 9.1 99.5 132.3 58
s.d. 10 594.3 198.2 23.6 134.3 175.6 14.6
Number 336 336 155 336 336 336
aRatio of PSA and hK2 concentrations calculated only for cytosols in which PSA ³ 0.6 ng g–1 and hK2 ³ 3.8 ng g–1.
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Figure 1 Frequency distributions of logarithmically-transformed PSA (A)
and hK2 (B) concentrations in 336 breast tumour cytosols
A
B
P
S
A
 
c
o
n
c
e
n
t
r
a
t
i
o
n
 
(
n
g
 
g
–
1
)
hK2 concentration (ng g–1)
0 2 04 06 08 0 1 0 0
3500
3000
2500
2000
1500
1000
500
0
500
400
300
200
100
0
0 200 400 600
hK2 concentration (ng g–1)
P
S
A
 
c
o
n
c
e
n
t
r
a
t
i
o
n
 
(
n
g
 
g
–
1
)
Figure 2 Scatterplots showing pairs of PSA and hK2 concentrations in:
(A) 335 breast tumour cytosols, excluding one specimen with a PSA and an
hK2 concentration of approximately 400 000 ng g–1 and 7000 ng g–1,
respectively; (B) 306 cytosols containing hK2 < 100 ng g–1tion (s.d.) of 21 820.5 ng l–1. Concentrations of hK2 ranged from 0
to 7181 ng l–1 and had a median, mean, and s.d. of 6.6 ng l–1,
48.8 ng l–1, and 401.9 ng 1–1 respectively. The frequency distribu-
tions of all adjusted PSA and hK2 concentrations are shown as
histograms in Figure 1 and described in Table 1. Listed also in the
table are parameters describing the distributions of ER and PR
concentrations, of the PSA/hK2 ratio and of patient age at surgery.
Because the distributions of PSA and hK2 concentrations were
positively skewed, indicated by the greatly elevated mean values
compared to the respective 50th percentiles, non-parametric statis-
tical procedures using the ranks of the values rather than the values
themselves were used to examine relationships between them and
the other known parameters. The calculation of Spearman correla-
tion coefficients revealed positive correlation between the pairs of
PSA and hK2 concentrations (r = 0.59, P = 0.0001). The wide
dispersion of pairs of PSA and hK2 values from a linear relation-
ship is shown in Figure 2. Statistically significant correlations
between PSA or hK2 and ER were not found, although positive
correlations between PSA (r = 0.25, P = 0.0001) or hK2 (r = 0.22,
P = 0.0001) and PR were revealed. There was a moderately strong
correlation between ER and PR (r = 0.52, P = 0.0001). Patient age
was positively correlated with ER concentration (r = 0.35, P =
0.0001) and negatively correlated with PSA (r = –0.12, P = 0.03),
although correlation between age and PR or hK2 were not evident
in our series (data not shown).
Categorization of PSA and hK2 concentrations as positive or
negative on the basis of cutoff points equal to or greater than the
70th percentiles of the respective distributions, and use of
Wilcoxon rank sum tests to compare concentrations of each
protein between groups of specimens classified as positive or
negative for the other protein, yielded similar findings as the corre-
lation analysis (Table 2). Selection of the cutoff points were arbi-
trary but consistent with previously used values (Diamandis et al,
1994; Yu et al, 1995). PSA-positive breast tumour cytosols were
thus found to have a higher median hK2 level than PSA-negative
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Table 2 Wilcoxon rank sum analysis of associations between PSA and hK2 concentrations, steroid hormone
receptor status, and patient age
Variable Number Median PSA (ng g–1) P Median hK2 (ng g–1) P
PSAa
PSA (–) 235 – 0
PSA (+) 101 – 15 <0.001
hK2b
hK2 (–) 235 1.4 –
hK2 (+) 101 97 <0.001 –
Age
<57 years 166 5.3 4.4
>57 years 170 2.9 0.06 3.9 0.24
ER statusc
ER (–) 73 0.8 0
ER (+) 263 5.3 <0.001 5.0 <0.001
PR statusc
PR (–) 74 0.8 0
PR (+) 262 5.4 <0.001 5.2 <0.001
Combined ER, PR statusc
ER (–), PR (–) 47 0 0
ER (–), PR (+) 26 5.4 7.0
ER (+), PR (–) 27 3.4 4.8
ER (+), PR (+) 236 5.4 <0.001 5.0 <0.001
aPSA-positivity based on cut-off level (23 ng g–1) equal to the 70th percentile of the PSA distribution. bhK2-
positivity based on a cut-off level (7 ng g–1) equal to the 70th percentile of the hK2 distribution. cER- and PR-
positivity based on cut-off levels of 5 fmol mg–1.
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Figure 3 Gel filtration HPLC chromatograms of two breast tumour cytosols
containing approximately: (A) 400 000 ng l–1 PSA and 7000 ng l–1 hK2;
(B) 3000 ng l–1 PSA and 600 ng l–1 hK2. The molecular weight markers eluted
in fractions 25–26 (Mr 670 000), 32–33 (Mr 158 000), 39–40 (Mr 44 000),
44–45 (Mr 17 000) and 52–53 (Mr 1400)specimens. This association was mirrored by the relatively
elevated PSA concentrations among hK2-positive tumour extracts
compared to hK2-negative specimens. Whereas significant
associations between patient age and neither PSA nor hK2 were
revealed by this analysis, the increased PSA concentrations in
patients less than 57 years of age was of borderline significance.
Higher concentrations of both proteins were strongly associated
with ER and PR expression, relationships that were evident from
comparisons of median PSA or hK2 levels between tumours with
negative and positive status for individual receptors, as well as
between tumours that were negative for both receptors, positive
for PR but negative for ER, positive for ER but negative for PR,
and positive for both receptors. The ratio of PSA to hK2 concen-
trations exceeding the detection limits of the immunoassays varied
considerably but, in general, PSA levels were higher by
approximately twofold (Table 1).
The molecular weights of the species reactive to the antibodies
used in the PSA and hK2 assays were estimated by HPLC in two
cytosols containing high contents of these proteins. As shown in
Figure 3, the fractions with maximal immunoreactivity in both
assays corresponded to a Mr of approximately 30 000. For PSA, a
minor fraction (< 5%) which eluted at Mr of approximately
100 000 likely represents PSA bound to the proteinase inhibitor
a1-antichymotrypsin, as shown previously (Ferguson et al, 1996).
Despite the necessity to dilute the NAFs by a factor of 100 to
200-fold before analysis (due to their small sample volumes), the
measurement of both PSA and hK2 in this fluid was feasible. The
median PSA content of the 31 diluted NAFs was 774 ng g–1 (range
20–3635 ng g–1) and the median hK2 content was 20 ng g–1 (range
0–171 ng g–1). Only one NAF had undetectable hK2. Spearman
analysis between PSA and hK2 concentrations in the NAFs
revealed a significant correlation (r = 0.53, P = 0.002). Based on a
total protein content of undiluted NAF of approximately 100 g l–1,
the median PSA and hK2 concentrations in undiluted NAF were
estimated to be approximately 77 000 ng l–1 and 2000 ng l–1
respectively.
DISCUSSION
Similarities between two of the most frequently diagnosed human
malignancies – breast and prostate cancers – have recently been
shown to include the expression of biochemical markers tradition-
ally thought to be specific to prostatic tissue. PSA, currently used
in prostate cancer screening and management, has been shown by
our group to be present in normal and neoplastic breast epithelium
(Diamandis and Yu, 1997) and to be an independent prognostic
indicator for breast cancer (Yu et al, 1995, 1998). However,
whether the prognostic value of PSA expression is restricted to
particular subgroups of breast cancer patients, such as those
defined by ER status, lymph node status, or adjuvant treatment
remains unclear (Yu et al, 1998). In this report, we present
evidence for the expression in breast tissue of another prostate-
associated protein, hK2 (McCormack et al, 1995). Although an in
vitro study of a breast carcinoma cell line has reported hK2 expres-
sion to be up-regulated by steroid hormones (Hsieh et al, 1997), to
our knowledge this study is the first in which hK2 expression has
been demonstrated in clinical breast tumour specimens. The devel-
opment of sensitive and specific immunoassays discriminating
between the homologous PSA and hK2 proteins (Ferguson et al,
1996; Black et al, 1999), subsequent to the availability of
improved antibodies, enabled us to determine the expression
pattern of these proteins relative to each other and to patient age
and hormone receptor status in a series of newly diagnosed breast
carcinomas. Because of the very short post-operative follow-up for
these patients, the prognostic implications of hK2 expression
compared to that of PSA could not be evaluated.
Of the 336 breast tumour extracts prepared for routine steroid
hormone receptor quantification, approximately 70% and 50%
contained detectable levels of PSA and hK2 respectively. The
median PSA concentration in the tumour extracts was approxi-
mately 107–108 orders of magnitude lower than the level of PSA
typically detected in seminal fluid, and about 500-fold lower than
serum concentrations of PSA in males, which range from 0 to
4 mg l–1 (McCormack et al, 1995). The median hK2 levels in breast
tumours are approximately 105-fold lower than that of seminal
fluid. Concentrations of both proteins differed widely between
specimens although, in general, those of PSA were 3- to 5-fold
higher than those of hK2 – a trend previously observed by our
group in the sera of males (Black et al, 1999). There is some
discrepancy among the reported ratios of circulating PSA and
hK2, likely due to differences in assay design and calibration.
These inconsistencies are indicative of a need for hK2 assay stan-
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Oestrogen Progestin
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Pro-PSA+hK2 Active PSA Downstream substrates
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Figure 4 Hypothetical model of PSA and hK2 regulation in breast tissue. ER, PR and AR are oestrogen, progesterone and androgen receptors respectively.
Ligand binding to PR and AR may induce in vivo expression of both pro-PSA and hK2, while ligand binding to ER may up-regulate PR expression. Activation of
pro-PSA to mature, enzymatically active PSA may be induced by hK2. Both PSA and hK2 may act on downstream substrates to elicit biological effectsdardization, as has long been the case with PSA assays.
Throughout the range of PSA and hK2 concentrations, a statisti-
cally significant positive correlation was found. We have also
established in this series of tumours, as we have in previous
cohorts of breast cancer patients (Diamandis et al, 1994; Yu et al,
1998), a negative correlation between PSA expression and patient
age. Furthermore, the results of Wilcoxon rank sum tests
suggested significantly increased expression of both PSA and hK2
in the presence of ER and PR. While PSA and hK2 concentrations
tended to be relatively higher in tumours also expressing ER, we
speculate that these latter associations arose indirectly from the
strong correlation between ER and PR generally believed to reflect
the ability of oestrogen, acting through its receptor, to induce PR
expression (McGuire et al, 1977). Support for the notion that PR
but not ER is necessary for induction of both PSA and hK2 gene
expression has been provided by cell culture studies (Hsieh et al,
1997; Zarghami et al, 1997), as well as the findings reported here
of stronger correlations between PSA or hK2 and PR than between
either kallikrein and ER. In contrast to the associations between
PSA or hK2 and steroid receptor status, the two proteins differed
somewhat with respect to their associations with patient age.
Younger patients showed a tendency to be more frequently posi-
tive for PSA, in accordance with our previously reported data
(Diamandis et al, 1994; Yu et al, 1994, 1998), but this relationship
was not evident in the case of hK2 expression.
The detection of hK2 in NAF collected from women without
apparent malignant disease represents, to our knowledge, a novel
finding. Like PSA, which we had previously shown to be present
in NAF (Yu et al, 1995, 1996; Foretova et al, 1996; Sauter et al,
1996), hK2 was found at concentrations comparable to those
found in seminal plasma. The hK2 concentrations in these 31 spec-
imens were correlated to those of PSA, but were on average about
35 times lower.
The phenomenological data yielded from this study, together
with the work of other groups, suggests a possible model for the
roles of PSA and hK2 in breast tissue. PSA and hK2 have been
shown to be proteases with chymotrypsin-like and trypsin-like
activities respectively, and a functional link between these
enzymes may be the demonstrated ability of hK2 to proteolytically
convert inactive pro-PSA into the enzymatically active, mature
PSA which may act upon its physiologically relevant downstream
substrates (Kumar et al, 1997; Lovgren et al, 1997). Among the
candidate substrates for active PSA is IGFBP-3, cleavage of which
liberates the growth factor IGF-1 from its carrier protein (Cohen et
al, 1992). PSA may also regulate the activities of other cytokines
(Killian et al, 1993; Fichtner et al, 1996), and may itself have
growth factor activity (Lai et al, 1996). In addition to PSA, other
substrates for hK2 have not yet been identified but may also elicit
biological effects. As speculated in Figure 4, the expression of
these two enzymes by breast epithelial tissue, and their secretion
into mammary ducts, may therefore be directed by common regu-
latory factors including androgens and progestins. Because the
formalin-fixed, paraffin-embedded tissues corresponding to the
cytosolic extracts prepared for the breast cancer patients were not
available, immunohistochemical determination of the precise
cellular source of hK2 could not be performed. It is therefore not
presently known if both PSA and hK2 are synthesized by the same
cell types in vivo.
In conclusion, we report the presence of hK2 in cytosolic
extracts prepared from breast tumours and in secretions of normal
mammary tissues, and demonstrate that its expression is correlated
to the expression of PSA and to hormone receptor status, particu-
larly that of PR. Because the correlation between concentrations of
hK2 and PSA was not perfect, however, it remains possible that
hK2 expression may provide prognostic information for breast
cancer independently of that provided by PSA or other established
indicators of outcome. Future studies will aim to further charac-
terize the hK2–PSA interaction, to determine additional substrates
for hK2, to localize PSA and hK2 expression in the context of
cytologic features, as well as to address the clinical implications, if
any, of hK2 in breast cancer.
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